Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and SurVaxM in Progressing Metastatic Neuroendocrine Carcinomas
NCT06202066Phase 2Not yet recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SurVaxM in neuroendocrine carcinoma (NEC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
SurVaxM
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06202066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202066.